{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:37Z","timestamp":1790796217847,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute erythroid leukemia (AEL) is a rare subtype of acute myeloid leukemia (AML) primarily affecting older adults and was previously classified into erythroid\/myeloid and pure erythroid subtypes. In this pediatric AEL study, we evaluated morphologic, immunophenotypic, cytogenetic, molecular, and clinical data of 24 (1.2%) cases from all cases undergoing central pathology review in Children\u2019s Oncology Group trials AAML0531 and AAML1031. Of 24 cases, 5 had a pure erythroid phenotype, and 19 had an erythroid\/myeloid phenotype. NUP98 fusions were highly enriched in patients with AEL, occurring in 7 of 22 cases for which molecular data were available (31.8% vs 6.7% in other AML subtypes). Of 5 cases of pure erythroid leukemias (PELs), 3 had NUP98 fusions, and 4 had complex karyotypes. Erythroid\/myeloid leukemias were reclassified by using the 2017 World Health Organization hematopathology classification as: myelodysplastic syndrome (MDS) with excess blasts-1 (n = 3), MDS with excess blasts-2 (n = 7), AML (nonerythroid, n = 5), and unknown MDS\/AML (n = 4); the 5 cases of nonerythroid AML included 1 with an NUP98\u2013NSD1 fusion, 2 with myelodysplasia-related changes, and 1 with a complex karyotype. Three cases of MDS with excess blasts-2 also had NUP98 rearrangements. WT1 mutations were present in 5 of 14 cases, all erythroid\/myeloid leukemia. Outcomes assessment revealed statistically poorer overall survival (5-year, 20% \u00b1 36% vs 66% \u00b1 23%; P = .004) and event-free survival (5-year, 20% \u00b1 36% vs 46% \u00b1 23%; P = .019) for those with PEL than those with erythroid\/myeloid leukemia. Our study supports that AEL is a morphologically and genetically heterogeneous entity that is enriched in NUP98 fusions, with the pure erythroid subtype associated with particularly adverse outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002712","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:20:56Z","timestamp":1607473256000},"page":"6000-6008","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Acute erythroid leukemia is enriched in\n                    <i>NUP98<\/i>\n                    fusions: a report from the Children\u2019s Oncology Group"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-1252","authenticated-orcid":false,"given":"Karen M.","family":"Chisholm","sequence":"first","affiliation":[{"name":"Department of Laboratories, Seattle Children\u2019s Hospital, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Heerema-McKenney","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-0180","authenticated-orcid":false,"given":"John K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy A.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, University of Minnesota Medical Center, Fairview, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana C.","family":"Raimondi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group, Monrovia, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5644","authenticated-orcid":false,"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Sung","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2893","authenticated-orcid":false,"given":"Alan S.","family":"Gamis","sequence":"additional","affiliation":[{"name":"Children\u2019s Mercy Hospitals & Clinics, Kansas City, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-2128","authenticated-orcid":false,"given":"Samir B.","family":"Kahwash","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"2020120711304511100_B1","author":"Howlader","year":"2019"},{"issue":"4","key":"2020120711304511100_B2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"4","key":"2020120711304511100_B3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"2020120711304511100_B4","first-page":"91","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Brunning","year":"2001"},{"issue":"10","key":"2020120711304511100_B5","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2009-09-243964","article-title":"Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification","volume":"115","author":"Hasserjian","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2020120711304511100_B6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12185-008-0183-3","article-title":"Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children","volume":"88","author":"Honda","year":"2008","journal-title":"Int J Hematol"},{"issue":"2","key":"2020120711304511100_B7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10428194.2011.607526","article-title":"Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification","volume":"53","author":"Liu","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020120711304511100_B8","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2002-11-3459","article-title":"Diagnostic criteria for acute erythroleukemia","volume":"101","author":"Selby","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2020120711304511100_B9","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/modpathol.2008.142","article-title":"Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification","volume":"21","author":"Wang","year":"2008","journal-title":"Mod Pathol"},{"key":"2020120711304511100_B10","first-page":"156","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Arber","year":"2017"},{"issue":"1","key":"2020120711304511100_B11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pbc.20951","article-title":"Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group","volume":"49","author":"Barnard","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"11 pt 2","key":"2020120711304511100_B12","first-page":"4833","article-title":"Eastern Cooperative Oncology Group study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival","volume":"41","author":"Bennett","year":"1981","journal-title":"Cancer Res"},{"issue":"3","key":"2020120711304511100_B13","first-page":"348","article-title":"Childhood erythroleukemia: review of clinical and biological features","volume":"11","author":"Malkin","year":"1989","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"27","key":"2020120711304511100_B14","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020120711304511100_B15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","article-title":"Genomic subtyping and therapeutic targeting of acute erythroleukemia","volume":"51","author":"Iacobucci","year":"2019","journal-title":"Nat Genet"},{"issue":"7","key":"2020120711304511100_B16","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"key":"2020120711304511100_B17","first-page":"134","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Arber","year":"2008"},{"key":"2020120711304511100_B18","first-page":"130","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Arber","year":"2017"},{"key":"2020120711304511100_B19","first-page":"150","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Arber","year":"2017"},{"key":"2020120711304511100_B20","first-page":"98","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Hasserjian","year":"2017","edition":"Revised 4th ed."},{"issue":"3","key":"2020120711304511100_B21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The incidence and clinical significance of nucleophosmin mutations in childhood AML","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2020120711304511100_B22","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1182\/blood-2008-10-184747","article-title":"Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children\u2019s Oncology Group","volume":"113","author":"Ho","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2020120711304511100_B23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2010-02-268953","article-title":"Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children\u2019s Oncology Group","volume":"116","author":"Ho","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020120711304511100_B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2020120711304511100_B25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13059-019-1842-9","article-title":"Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods","volume":"20","author":"Haas","year":"2019","journal-title":"Genome Biol"},{"issue":"11","key":"2020120711304511100_B26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nmeth.1517","article-title":"De novo assembly and analysis of RNA-seq data","volume":"7","author":"Robertson","year":"2010","journal-title":"Nat Methods"},{"issue":"1","key":"2020120711304511100_B27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions [published corrections appear in Nat Med. 2018;24(4):526 and Nat Med. 2019;25(3):530]","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"282","key":"2020120711304511100_B28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2020120711304511100_B29","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002","edition":"2nd ed."},{"issue":"3","key":"2020120711304511100_B30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/modpathol.2010.194","article-title":"Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification","volume":"24","author":"Liu","year":"2011","journal-title":"Mod Pathol"},{"issue":"3","key":"2020120711304511100_B31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2016.267","article-title":"NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis","volume":"31","author":"Struski","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2020120711304511100_B32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2016.361","article-title":"NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group","volume":"31","author":"Bisio","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2020120711304511100_B33","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2013.87","article-title":"NUP98\/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern","volume":"27","author":"de Rooij","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"2020120711304511100_B34","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"de Rooij","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020120711304511100_B35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.20308","article-title":"Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene","volume":"45","author":"van Zutven","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2020120711304511100_B36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/gcc.22444","article-title":"Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome","volume":"56","author":"Hara","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2020120711304511100_B37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.3772","article-title":"Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes","volume":"49","author":"de Rooij","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"2020120711304511100_B38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1179\/acb.2007.047","article-title":"Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature","volume":"62","author":"Dani\u00ebls","year":"2007","journal-title":"Acta Clin Belg"},{"issue":"1","key":"2020120711304511100_B39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1309\/AJCPRKYAT6EZQHC7","article-title":"Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics: a guide to a number of perplexing entities","volume":"144","author":"Wang","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2020120711304511100_B40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1365-2141.1998.00904.x","article-title":"Coexpression of erythroid and megakaryocytic genes in acute erythroblastic (FAB M6) and megakaryoblastic (FAB M7) leukaemias","volume":"102","author":"Linari","year":"1998","journal-title":"Br J Haematol"},{"issue":"9","key":"2020120711304511100_B41","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1080\/10428194.2019.1574002","article-title":"Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment","volume":"60","author":"Winestone","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/23\/6000\/1794001\/advancesadv2020002712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/23\/6000\/1794001\/advancesadv2020002712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:21:13Z","timestamp":1607473273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/23\/6000\/474412\/Acute-erythroid-leukemia-is-enriched-in-NUP98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":41,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002712","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}